KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) Revenue (2016 - 2026)

Boston Scientific's Revenue history spans 18 years, with the latest figure at $5.2 billion for Q1 2026.

  • On a quarterly basis, Revenue rose 11.58% to $5.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $20.6 billion, a 17.44% increase, with the full-year FY2025 number at $20.1 billion, up 19.87% from a year prior.
  • Revenue hit $5.2 billion in Q1 2026 for Boston Scientific, down from $5.3 billion in the prior quarter.
  • Over the last five years, Revenue for BSX hit a ceiling of $5.3 billion in Q4 2025 and a floor of $3.0 billion in Q1 2022.
  • Historically, Revenue has averaged $4.1 billion across 5 years, with a median of $3.9 billion in 2024.
  • Biggest five-year swings in Revenue: rose 3.68% in 2022 and later rose 22.84% in 2025.
  • Tracing BSX's Revenue over 5 years: stood at $3.2 billion in 2022, then grew by 14.9% to $3.7 billion in 2023, then increased by 22.44% to $4.6 billion in 2024, then rose by 15.9% to $5.3 billion in 2025, then fell by 1.57% to $5.2 billion in 2026.
  • Business Quant data shows Revenue for BSX at $5.2 billion in Q1 2026, $5.3 billion in Q4 2025, and $5.1 billion in Q3 2025.